The nocebo effect challenges the non-medical infliximab switch in practice.
European journal of clinical pharmacology(2018)
摘要
In inflammatory bowel disease and rheumatological patients, similar effectiveness and safety were demonstrated on the transition into infliximab biosimilar. In our series, patient empowerment and registration of treatment outcomes delineated biosimilar transition, an approach that hypothetically could reduce nocebo response rates which are relevant to account for regarding biosimilar implementation.
更多查看译文
关键词
Ankylosing spondylitis,Crohn’s disease,Inflammatory bowel disease,Nocebo-effect,Non-medical switch,Psoriatic arthritis,Rheumatoid arthritis,Ulcerative colitis
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要